Novartis And Cell Therapeutics Suspend Xyotax Development
This article was originally published in The Pink Sheet Daily
Executive Summary
CTI and Novartis are temporarily suspending the PIONEER lung cancer trial to evaluate mortality signals and amend the study protocol.